Notable insider buying and selling activity across public companies.
Tracking and analysis of reported insider transactions, including executive and director buying or selling. Insider activity can offer insight into internal confidence, valuation perceptions, and potential inflection points.
10,710 total articles
ImmunityBio director Christobel Selecky sold 25,000 shares on February 23, 2026, for $10 apiece, generating $250,000. On the same day she exercised options to buy 25,000 shares at $2.98, a transaction worth $74,500. The sale was carried out under a Rule 10b5-1 plan. The company has reported substantial revenue growth for its cancer therapy ANKTIVA,…
Palantir Technologies CEO Alexander C. Karp sold $65.9 million worth of Class A common stock in a series of transactions on February 20, 2026, and completed several conversions of Class B shares to Class A. The stock is trading below the sales range and is viewed by one service as overvalued versus Fair Value, even as analysts upgraded the shares a…
Palantir Technologies director Stephen Andrew Cohen sold $43.7 million of Class A Common Stock on February 20, 2026 across a series of transactions. The company’s shares have fallen 27.5% year-to-date and trade at a high price-to-earnings multiple. Cohen also converted Class B shares to Class A and restricted stock units were exercised into Class B…
Barry J. Simon, a director at ImmunityBio, sold 175,000 shares of the company’s common stock in late February 2026 for roughly $1.78 million under a pre-arranged Rule 10b5-1 plan. The transactions occurred as the stock traded above its 52-week high amid substantial revenue growth for the company’s cancer therapy ANKTIVA and new distribution deals i…
KalVista Pharmaceuticals CFO Brian Piekos sold 1,767 shares on February 23, 2026, netting $27,506 at a weighted average price of $15.5668 per share. Earlier in the week he exercised options on 5,000 shares and converted 5,000 restricted stock units into common stock. The insider moves come as KalVista reports preliminary fourth-quarter 2025 revenue…
KalVista Pharmaceuticals Chief Medical Officer Paul K. Audhya sold 5,354 shares on February 23, 2026, generating about $83,344. The sale followed the exercise and conversion of 11,250 restricted stock units into common shares on February 21 and 22. KalVista's stock trades around $15.77, and the company reported preliminary global EKTERLY sales of r…
Nicole Sweeny, chief commercial officer of KalVista Pharmaceuticals (KALV), sold 3,975 shares of common stock on February 23, 2026, to satisfy tax-withholding tied to vested RSUs. The sale totaled about $61,878 at a weighted average price of $15.5668. The company reported preliminary fourth-quarter 2025 EKTERLY revenue of roughly $35 million, well …
Christopher Yea, Chief Development Officer at KalVista Pharmaceuticals (KALV), sold 4,347 shares on February 23, 2026, to satisfy tax-withholding obligations stemming from the vesting and settlement of restricted stock units. The transaction was non-discretionary, according to a Form 4 filing. Separately, KalVista reported roughly $35 million in gl…
KalVista Pharmaceuticals Chief Executive Officer Benjamin L. Palleiko sold 10,034 shares on February 23, 2026 to cover tax withholding obligations, realizing roughly $156,197. The company reported about $35 million in fourth-quarter 2025 revenue from its oral HAE treatment EKTERLY, contributing to approximately $49 million in full-year sales after …
Reddit Chief Operating Officer Jennifer L. Wong sold a combined $5.6 million of Class A Common Stock on February 24, 2026, through a series of transactions executed at prices between $141.82 and $147.47. The divestiture included shares sold directly and via the MorMa Trust, and followed a company withholding of shares to cover tax obligations. The …
Reddit Chief Technology Officer Christopher Brian Slowe sold $2.74 million worth of Class A Common Stock on February 23 in a series of transactions that followed option exercises and a recent award of shares. The insider activity coincides with robust fourth-quarter 2025 financial results for Reddit and comes against a backdrop of regulatory penalt…
Michael Warren Vostrizansky, a director at Neptune Insurance Holdings Inc (NP), purchased 23,000 shares of Class A Common Stock on February 20, 2026, investing $494,414. The buy occurred as the stock trades below the purchase price and following a wave of analyst upgrades spurred by better-than-expected fourth-quarter adjusted EBITDA and revised re…
Renee M. Bacon, senior vice president for sales and operations at Murphy USA Inc. (NYSE: MUSA), executed a sale of 2,844 shares on February 23, 2026, generating roughly $1.105 million. The transaction, recorded in a Form 4 filing with the Securities and Exchange Commission, leaves Bacon with a direct holding of 3,083.3 shares. Separately, Murphy US…
Director Milton C. Blackmore disclosed a set of transactions in Innospec Inc. (IOSP) during late February. On February 20, Blackmore sold 1,030 shares at $81.84 apiece for $84,296 and on the same day exercised options to acquire 1,030 shares at an exercise price of $44.18 for a reported total of $45,505. On February 23 he recorded the acquisition o…
Innospec INC director Larry Padfield completed a set of transactions in late February 2026 that included the sale of 1,030 common shares, the exercise of options for an identical number of shares, and the vesting of restricted stock units. The trades occurred as the specialty chemicals firm trades below a referenced fair value estimate and continue…
Honeywell International director Grace Lieblein sold 5,857 shares of common stock on February 23, 2026, for about $1.4 million and exercised options to acquire 7,777 shares the same day. The transactions occurred near the stock's 52-week high and come as the company faces valuation scrutiny and completes strategic moves including a reduced-price ac…
Judy Bruner, a member of Applied Materials Inc's board, sold a combined $1.49 million of company stock on February 23, 2026, through transactions executed by a family trust. The sales occurred with the share price trading near its 52-week top, while analysts continue to raise targets and the stock is described as appearing overvalued by InvestingPr…
Nadia Waheed, Chief Medical Officer at Ocular Therapeutix, sold 3,510 shares on February 20, 2026, to satisfy tax withholding tied to recently vested restricted stock units. The sale, disclosed in a Form 4 filing, followed a pre-arranged automatic instruction adopted in June 2024. The stock has been volatile amid positive Phase 3 SOL-1 data for AXP…
Applied Materials Controller and Chief Accounting Officer Adam Sanders sold 534 shares on February 24, 2026, generating proceeds of $202,471. After the sale he retains 4,625 shares, the bulk of which are restricted stock units scheduled to convert in installments from April 2026 through January 2030, subject to continued employment. Separately, sev…
Vonne Elizabeth Karpinski, Executive Vice President and General Counsel of Advanced Energy Industries Inc (AEIS), sold 964.001 shares of company stock on February 23, 2026, under a Rule 10b5-1 trading plan adopted November 12, 2025. The two transactions ranged from $328.42 to $329.76 per share and totaled about $316,597. After the sale Karpinski ho…
Sequoia-affiliated director Reed Andrew Phillips bought roughly $36.5 million of Figma Inc. (FIG) Class A common stock across two days in late February 2026, adding 1,466,852 shares through SC Expansion Fund II Management, L.P. The insider acquisitions coincide with robust fourth-quarter results and forward guidance for fiscal 2026, even as the sha…
Auburn National Bancorporation director Conn Walton T Jr. bought 200 shares of company stock on February 24, 2026, in two transactions at $24.75 per share, representing $4,950 in total. The company recently announced a quarterly cash dividend of $0.27 per share for the first quarter of 2026, payable March 25 to shareholders of record March 10. Aubu…
Cynthia L. Tregillis, Western Digital's Chief Legal Officer and Corporate Secretary, sold 438 shares of common stock on February 23 and 24, 2026, for about $123,661 under a Rule 10b5-1 plan. The transactions accompany other insider activity to cover taxes and follow corporate moves including redemption of 4.750% senior notes due 2026, a planned San…
Amazon President and CEO Andrew R. Jassy sold 20,072 shares of Amazon common stock for a total of $4.08 million on February 23, 2026 under a Rule 10b5-1 trading plan, while also acquiring 49,680 shares through the exercise of restricted stock units. The company’s stock was trading at $208.59 at the time, roughly 10% lower year-to-date, with analysi…
Adam David Sachs, president of Vicarious Surgical Inc. (NASDAQ: RBOT), sold 942 shares of Class A common stock on February 20, 2026, for $1,966 to meet tax-withholding obligations tied to vested restricted stock units. The sale occurred at a weighted average price of $2.0878, with prices ranging from $1.845 to $2.290. Following the transaction, Sac…
